וסיקר 10 מ"ג - Vesicare 10 mg
ש××× ×× !
×ת×ר××: 07/02/2025 ×תק××× ××××¢× ×× ×©×××ק ×תר××¤× ××פסק ×צ××ת×ת.
×ת×ר××: 07/02/2025 ×תק××× ××××¢× ×× ×©×××ק ×תר××¤× ××פסק ×צ××ת×ת.
×ק×ר: ××©×¨× ××ר×××ת - ××××¢×ת ×¢× ×פסקת ש×××ק תר×פ×ת
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | G04BD Drugs for urinary frequency and incontinence | ||||||||||||||||||
| ×ר××× ×¤×¢×× (ATC5) | Â
| ||||||||||||||||||
| צ×רת ××ª× | פ××× - PER OS | ||||||||||||||||||
| צ×רת ××× ×× | ×××××ת ×צ×פ×ת פ×××, FILM COATED TABLETS ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | ||||||||||||||||||
| ×ת×××× | Vesicare is indicated for symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome.
| ||||||||||||||||||
| |||||||||||||||||||
| ×ת××ת ××× ×× | Posology and method of administration | ||||||||||||||||||
| ×ת××××ת × ×× | Contraindications | ||||||||||||||||||
| ת×פע×ת ××××× | Undesirable effects | ||||||||||||||||||
| ת××××ת ××× ×ª×¨×פת××ת | Interaction with other medicinal products and other forms of interaction | ||||||||||||||||||
| ש×××ש ×××ר××× ××× ×§× | Pregnancy and Lactation | ||||||||||||||||||
| פר×ק×××× ×××§× | Pharmacodynamic Properties | ||||||||||||||||||
| פר×ק×ק×× ×××§× | Pharmacokinetic Properties | ||||||||||||||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  | ||||||||||||||||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ×ס×קר 10 ×"× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | ASTELLAS PHARMA EUROPE B.V, THE NETHERLANDS |
| ×©× ××¢× ×ר×ש×× | CTS LTD |
| ר×ש××× | ת×ר×× ××ש×: 05/2005. ר×ש××× ×ת×ר××: 11/2011 |
| ת×ר×× ×¢×××× ××ר×× | 07/02/2025 |
ת××× ×ª ×ר×××
השינוי האחרון נעשה בֹ־7 בפברואר 2025 ב־20:32